CareDx, Inc. (CDNA) Major Shareholder Neil Gagnon Acquires 35,119 Shares
CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon purchased 35,119 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The stock was bought at an average price of $2.92 per share, for a total transaction of $102,547.48. Following the transaction, the insider now directly owns 890,473 shares in the company, valued at $2,600,181.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Monday, July 24th, Neil Gagnon purchased 1,486 shares of CareDx stock. The stock was bought at an average price of $1.23 per share, for a total transaction of $1,827.78.
- On Thursday, June 29th, Neil Gagnon purchased 1,808 shares of CareDx stock. The stock was bought at an average price of $1.11 per share, for a total transaction of $2,006.88.
- On Friday, June 23rd, Neil Gagnon purchased 63,120 shares of CareDx stock. The stock was bought at an average price of $1.10 per share, for a total transaction of $69,432.00.
CareDx, Inc. (CDNA) opened at 2.72 on Tuesday. The firm’s market cap is $61.31 million. CareDx, Inc. has a 52-week low of $0.76 and a 52-week high of $4.98. The firm’s 50-day moving average price is $1.56 and its 200 day moving average price is $1.45.
CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.19). CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. The firm had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.87 million. On average, equities analysts anticipate that CareDx, Inc. will post ($0.82) earnings per share for the current year.
WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/29/caredx-inc-cdna-major-shareholder-neil-gagnon-acquires-35119-shares.html.
Institutional investors have recently made changes to their positions in the company. Gagnon Securities LLC increased its position in shares of CareDx by 2.9% in the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after buying an additional 57,954 shares in the last quarter. Royce & Associates LP increased its position in shares of CareDx by 23.5% in the first quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock worth $737,000 after buying an additional 100,111 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in shares of CareDx during the second quarter worth $212,000. 29.15% of the stock is owned by institutional investors.
CDNA has been the topic of several recent analyst reports. Zacks Investment Research upgraded CareDx from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Thursday, May 25th. ValuEngine cut CareDx from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.